---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Diagnosis"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Diagnosis. Topics: Clinical diagnostic criteria: 2010 consensus criteria for typical and atypical Rett syndrome, Young children: provisional diagnosis before regression is evident, Validation of the criteria in the US Natural History Study: 819 participants, Genetic testing: MECP2 sequencing with deletion and duplication analysis, and 5 further topics. 9 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/diagnosis"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Clinical diagnostic criteria: 2010 consensus criteria for typical and atypical Rett syndrome

| Criterion | Quoted criterion |
| --- | --- |
| Feature that should prompt consideration | “Consider diagnosis when postnatal deceleration of head growth observed.” |
| Required for typical RTT | “A period of regression followed by recovery or stabilization” |
| Required for typical RTT | “All main criteria and all exclusion criteria” |
| Required for typical RTT | “Supportive criteria are not required, although often present in typical RTT” |
| Required for atypical RTT | “At least 2 out of the 4 main criteria” |
| Required for atypical RTT | “5 out of 11 supportive criteria” |
| Main criterion 1 | “Partial or complete loss of acquired purposeful hand skills.” |
| Main criterion 2 | “Partial or complete loss of acquired spoken language” |
| Main criterion 3 | “Gait abnormalities: Impaired (dyspraxic) or absence of ability.” |
| Main criterion 4 | “Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing and washing/rubbing automatisms” |
| Exclusion criterion for typical RTT | “Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, or severe infection that causes neurological problems” |
| Exclusion criterion for typical RTT | “Grossly abnormal psychomotor development in first 6 months of life” |

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

> “We limited the necessary criteria to the presence of regression plus four main criteria that are absolutely required for the diagnosis of typical RTT.”
> “In these new criteria, history of regression and ALL of the necessary and exclusion criteria MUST be met to make the diagnosis of typical RTT, without exception.”
> “we state that for the diagnosis of atypical RTT an individual MUST have a period of regression followed by recovery or stabilization.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.5-2"></a>

### Young children: provisional diagnosis before regression is evident

> “Because MECP2 mutations are now identified in some individuals prior to any clear evidence of regression, the diagnosis of”
> “RTT should be given to those individuals under 3 years old who have not lost any skills but otherwise have clinical features suggestive of RTT. These individuals should be reassessed every 6–12 months for evidence of regression. If regression manifests, the diagnosis should then be changed to definite RTT. However, if the child does not show any evidence of regression by 5 years, the diagnosis of RTT should be questioned.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.5-3"></a>

### Validation of the criteria in the US Natural History Study: 819 participants

> “The present analysis was conducted on 819 participants enrolled as of February 28, 2010, to assess the recently modified clinical criteria.”
> “Of 765 females fulfilling criteria for classic or variant RTT, 653 (85.4%) were diagnosed as classic and 112 (14.6%) were classified as variant. A mutation was identified in 95% of 653 females with classic and 73.2% of 112 females with variant RTT”
> “Abnormal deceleration in the rate of head growth was noted in 82%”
> “For classic RTT, these core criteria are sufficient for diagnosis as none of the eight 2002 supportive criteria is noted uniformly. For variant RTT, diagnosis requires application of both main (2 of 4) and supportive (5 of 11) criteria.”

Source: [Percy et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3021984/)

<a id="topic-2.2.1.5-4"></a>

### Genetic testing: MECP2 sequencing with deletion and duplication analysis

> “For suspicion of RTT, MECP2 gene sequencing and MLPA testing are recommended. MLPA testing is needed to detect deletions otherwise missed by sequencing; this test is necessary if no abnormalities are found by sequencing. Referral to a geneticist or genetic counsellor is recommended to review recurrence risks and answer related questions. Genetic testing results are essential for enrolment in clinical trials.”
> “Complete genetic testing involves sequencing and methods to detect larger deletions (eg, multiplex ligation-dependent probe amplification) of the MECP2 gene.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

> “Second, thorough and complete genetic testing for mutations in MECP2 should be performed on all participants. This would include sequencing of the coding region as well as methods such as MLPA, quantitative PCR, microarray methods, or Southern blotting to detect large DNA rearrangements.”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.5-5"></a>

### Genetic testing: diagnostic yield of next-generation sequencing in 1,577 patients with a Rett-like presentation

> “We studied 1577 patients with RTT-like clinical diagnoses and reviewed patients who were previously studied and thought to have RTT genes by Sanger sequencing. Genetically, 477 of 1577 patients with a RTT-like suspicion have been diagnosed. Positive results were found in 30% by Sanger sequencing, 23% with a custom panel, 24% with a commercial panel and 32% with whole exome sequencing.”

Source: [Vidal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5613000/)

<a id="topic-2.2.1.5-6"></a>

### Genetic testing: missed variant after repeated sequencing

> “Here, we describe a young woman with clinically diagnosed Typical RTT syndrome who lacked a genetic diagnosis despite 20 years of investigation and multiple rounds of sequencing the MECP2 gene.”
> “This case illustrates the evolving landscape of genetic testing technologies and the limitations of Next Generation (NextGen) sequencing due to deletions, duplications and insertions.”

Source: [Abbott et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11502282/)

<a id="topic-2.2.1.5-7"></a>

### Age at diagnosis: US Natural History Study, 1,085 participants

> “Among 919 classic and 166 atypical RTT participants, median diagnosis age was 2.7 years (interquartile range 2.0–4.1) in classic and 3.8 years (interquartile range 2.3–6.9) in atypical RTT. Pediatricians made the diagnosis of classic RTT rarely (5.2%); however, proportion diagnosed by pediatricians increased since 2006.”
> “33% with microcephaly before 2.5 years were diagnosed after the median age of 2.7 years.”

Source: [Tarquinio et al. (2015a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4442062/)

<a id="topic-2.2.1.5-8"></a>

### Age at diagnosis: international caregiver survey, 756 caregivers

> “The mean and median age of diagnosis were 4.3. and 2.8 years, respectively (classic RTT mean 3.8 years, median 2.5 years; atypical RTT mean 5.7 years, median 3.9 years)”

Source: [Kaufmann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11323357/)

<a id="topic-2.2.1.5-9"></a>

### Age at diagnosis: trends and predictors of delay in Australian and international registries

> “The median age of Rett syndrome diagnosis decreased from 4.5 years if diagnosed before 2000 to 3.5 years if diagnosed after 1999.”

Source: [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/)

> “A total of 909 cases were included. An older age of diagnosis was associated with later loss of hand function and speech, later onset of hand stereotypies and the presence of the p.R133C or p.R294X MECP2 mutation.”
> “Cases with a p.R133C mutation (adjusted mean 76.5 months) and those with a p.R294X mutation (adjusted mean 69.6 months) had a later age of diagnosis compared to those with a p.T158M mutation (adjusted mean 50.5 months).”

Source: [Fehr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3906205/)

Additional sources: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/); [McKnight et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9135956/); [Kim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255539/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
